Last reviewed · How we verify
Betaxon (LEVOBETAXOLOL)
Betaxon (LEVOBETAXOLOL) is a small molecule drug developed by ALCON PHARMS LTD, targeting the beta-1 adrenergic receptor to treat ocular hypertension and open-angle glaucoma. It was FDA approved in 2000 and remains a branded product due to its off-patent status. As a beta-blocker, Betaxon works by reducing the production of fluid in the eye, thereby lowering intraocular pressure. Key safety considerations include potential effects on heart rate and blood pressure. Betaxon's commercial status and pharmacokinetic properties are not well-documented.
At a glance
| Generic name | LEVOBETAXOLOL |
|---|---|
| Sponsor | Alcon Pharms Ltd |
| Drug class | levobetaxolol |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 2000 |
Approved indications
- Ocular hypertension
- Open-angle glaucoma
Common side effects
Key clinical trials
- Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension (PHASE3)
- Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Betaxon CI brief — competitive landscape report
- Betaxon updates RSS · CI watch RSS
- Alcon Pharms Ltd portfolio CI